C. Ola Landgren
Aug 24, 2025, 14:21
C. Ola Landgren: Tempus Acquires Paige – Advancing AI-Powered Cancer Detection with Digital Pathology
C. Ola Landgren, Leader of Translational & Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared on LinkedIn:
“Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial intelligence-powered programs for spotting the signs of cancer. The deal includes Tempus paying out Paige’s remaining commitment to Microsoft Azure for its cloud-computing services.
Tempus set its eyes on Paige for its massive, anonymized dataset, which encompasses nearly 7 million digitized pathology slides and clinical data licensed from Memorial Sloan Kettering Cancer Center.”
More posts featuring C. Ola Landgren.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 24, 2025, 14:17
Aug 24, 2025, 14:02
Aug 24, 2025, 13:47
Aug 24, 2025, 13:46
Aug 24, 2025, 13:40
Aug 24, 2025, 13:37
Aug 24, 2025, 13:30